NASDAQ Healthcare Medical - Diagnostics & Research IMDX

Insight Molecular Diagnostics Inc.

$ 5.44 2.26 %

OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis. Additionally, OncoCyte provides a range of expert services, such as biomarker discovery, assay design and refinement, and clinical trial assistance, which encompass offering various biomarker tests to pharmaceutical partners. A strategic partnership with Life Technologies Corporation focuses on the collaborative development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, intended for integration with the Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was founded in 2009 and maintains its principal office in Irvine, California.

CEO: Joshua Riggs - https://imdxinc.com

Summary 30-Y Financials Dividend Analyst Key metrics Ownership / Senat
Price objectif

$12 120.59 %

Recommandation

Buy

DCF

$ -2.67

Loading data...

IMDX vs S&P500

Loading data...

No data available.

Quick ratio

2.51

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

-3.58

may indicate that the company is undervalued or has poor growth prospects.

EPS

-1.52

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

380.80 %

is generally considered excellent, indicating that the company is generating strong profits with its equity.

ROIC

-136.40 %

does not generate enough return to cover its financing costs, which indicates value destruction and may pose long-term profitability issues.

WACC

12.53

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

-0.29

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

-0.80

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

0.00 %

the dividend payout ratio is the measure of dividends paid out to shareholders relative to the company's net income.

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
1 indicates worrying financial health
Altman score
-15.61 indicates a high risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
2.35 indicates that the company has sufficient cash to cover its short-term debts
Debt Ratio
0.08 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.